

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – July 23, 2025 – 06:00 PM CET - [Oxurion NV](#) (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on July 23, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 21, 2025, it held 1,845,939 shares of the then outstanding 12,428,021 shares, and therefore crossed under the threshold (15%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

<u>Oxurion NV</u> Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

21/07/2025 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

15

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

12,428,021

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	2,460,942	1,845,939		14.85%	
TOTAL		1,845,939	0	14.85%	0.00%

+

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments						
After the transaction						
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	1,845,939 14.85%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 14 July 2025 (with settlement date on 16 July 2025), Atlas Special Opportunities II LLC sold 58,976 shares in Oxurion NV, as a result of which its shareholding decreased to 2,460,942 shares (= 19.80%, denominator = 12,428,021).
On 15 July 2025 (with settlement date on 17 July 2025), Atlas Special Opportunities II LLC sold 400,001 shares in Oxurion NV, as a result of which its shareholding decreased to 2,060,941 shares (= 16.58%, denominator = 12,428,021).
On 16 July 2025 (with settlement date on 18 July 2025), Atlas Special Opportunities II LLC sold 1 shares in Oxurion NV, as a result of which its shareholding decreased to 2,460,940 shares (= 16.58%, denominator = 12,428,021).
On 17 July 2025 (with settlement date on 21 July 2025), Atlas Special Opportunities II LLC sold 215,001 shares in Oxurion NV, as a result of which its shareholding decreased to 1,845,939 shares (= 14.85%, denominator = 12,428,021)

Done at New York
On 21/07/2025 (DD/MM/YYYY)
Name & capacity Patrick Vancie, Proxyholder

Signature 

For security reasons, the unsigned form in xlsx format should be transmitted to trp.fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in PDF format should also be transmitted.